News and Trends 21 Feb 2019
Microbiome Biotech Will Use Series B to Bring Treatments to Clinic
The Israeli biotech BiomX has raised €28M ($32M) to advance its treatments for acne and inflammatory bowel disease to the clinical stage. Investor interest is continuing in treatments based on the microbiome, which have the potential to treat a variety of conditions such as chronic inflammatory diseases, and even some forms of cancer. BiomX’s approach […]